Journals
  • Cell Reprogram. 2016 Nov;18(6):367-368. Identification of Stable OCT4+NANOG- State in Somatic Cell Reprogramming. Aalam SM, Manian KV, Bharathan SP, Mayuranathan T, Velayudhan SR.
  • J Cell Mol Med. 2016 Aug;20(8):1571-88. hiPSCs derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine. Sabapathy V, Kumar S.
  • Biomater. Tissue Eng.Volume 6, Number 7, July 2016, pp. 549-562. Decellularized Amniotic Membrane Scaffold Compared to Synthetic PLGA and Hybrid Scaffolds Exhibit Superlative Biomechanical Properties for Tissue Engineering Applications Vikram Sabapathy, Manju Hurakadli, Deepti Rana, Murugan Ramalingam, and Sanjay Kumar J.
  • Bone Joint Res. 2016 Jul;5(7):301-6. WISP3 mutational analysis in Indian patients diagnosed with progressive pseudorheumatoid dysplasia and report of a novel mutation at p.Y198. Madhuri V, Santhanam M, Rajagopal K, Sugumar LK, Balaji V.
  • Biotechnol Prog. 2016 May;32(3):554-67. Surface functionalization of nanobiomaterials for application in stem cell culture, tissue engineering, and regenerative medicine. Rana D, Ramasamy K, Leena M, Jiménez C, Campos J, Ibarra P, Haidar ZS, Ramalingam M.
  • RSC Adv., 2016, 6, 20475-20484. Cell-laden alginate/polyacrylamide beads as carriers for stem cell delivery: preparation and characterization. Deepti Rana, Aleya Tabasuma and Murugan Ramalingam.
  • Cell Stem Cell. 2016 Feb 4;18(2):214-28. The Dlk1-Gtl2 Locus Preserves LT-HSC Function by Inhibiting the PI3K-mTOR Pathway to Restrict Mitochondrial Metabolism. Qian P, He XC, Paulson A, Li Z, Tao F, Perry JM, Guo F, Zhao M, Zhi L, Venkatraman A, Haug JS, Parmely T, Li H, Dobrowsky RT, Ding WX, Kono T, Ferguson-Smith AC8, Li L.
  • Curr Stem Cell Res Ther. 2016;11(2):99-113. Quest for alternate personalized clinical source of MSCs: Advancing towards hiPSCs derived iMSCs. Sabapathy V, Kumar S.
  • Curr Stem Cell Res Ther. 2016;11(2):97-98. Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells: Ushering of a New Era in Personalized Cell Therapies. Pal R, Mariappan I, Velayudhan SR.
  • Semin Hematol. 2016 Jan;53(1):3-9. Factor VIII/factor IX prophylaxis for severe hemophilia. Carcao M, Srivastava A.
  • Eur J Immunol. 2016 Jan;46(1):154-66. Synergistic inhibition of PARP-1 and NF-?B signaling downregulates immune response against recombinant AAV2 vectors during hepatic gene therapy. Hareendran S, Ramakrishna B, Jayandharan GR.
  • Cytotherapy. 2016 Jan;18(1):120-3. Part 2: Making the "unproven" "proven". Weiss DJ, Rasko JE, Cuende N, Ruiz MA, Ho HN, Nordon R, Wilton S, Dominici M, Srivastava A.
  • Cytotherapy. 2016 Jan;18(1):117-9. Part 1: Defining unproven cellular therapies. Srivastava A, Mason C, Wagena E, Cuende N, Weiss DJ, Horwitz EM, Dominici M.